Role of adherent and invasive


Journal

Gut
ISSN: 1468-3288
Titre abrégé: Gut
Pays: England
ID NLM: 2985108R

Informations de publication

Date de publication:
01 2023
Historique:
received: 24 08 2021
accepted: 10 03 2022
pubmed: 2 4 2022
medline: 4 1 2023
entrez: 1 4 2022
Statut: ppublish

Résumé

We used the postoperative recurrence model to better understand the role of adherent and invasive From a prospective, multicentre cohort of operated patients with CD, AIEC identification was performed within the surgical specimen (M0) (N=181 patients) and the neoterminal ileum (n=119 patients/181) during colonoscopy performed 6 months after surgery (M6). Endoscopic postoperative recurrence was graded using Rutgeerts' index. The mucosa-associated microbiota was analysed by 16S sequencing at M0 and M6. Relative risks or ORs were adjusted on potential confounders. AIEC prevalence was twofold higher within the neoterminal ileum at M6 (30.3%) than within the surgical specimen (14.9%) (p<0.001). AIEC within the neoterminal ileum at M6 was associated with higher rate of early ileal lesions (i1) (41.6% vs 17.1%; aRR 3.49 (95% CI 1.01 to 12.04), p=0.048) or ileal lesions (i2b+i3) (38.2% vs 17.1%; aRR 3.45 (95% CI 1.06 to 11.30), p=0.040) compared with no lesion (i0). AIEC within the surgical specimen was predictive of higher risk of i2b-endoscopic postoperative recurrence (POR) (aOR 2.54 (95% CI 1.01 to 6.44), p=0.049) and severe endoscopic POR (aOR 3.36 (95% CI 1.25 to 9.06), p=0.017). While only 5.0% (6/119) of the patients were AIEC-positive at both M0 and M6, 43.7% (52/119), patients with history of positive test for AIEC (M0 or M6) had higher risk of ileal endoscopic POR (aOR 2.32 (95% CI 1.01 to 5.39), p=0.048)), i2b-endoscopic postoperative recurrence (aOR 2.41 (95% CI 1.01 to 5.74); p=0.048) and severe endoscopic postoperative (aOR=3.84 (95% CI 1.32 to 11.18), p=0.013). AIEC colonisation was associated with a specific microbiota signature including increased abundance of Based on the postoperative recurrence model, our data support the idea that AIEC are involved in the early steps of ileal CD. NCT03458195.

Identifiants

pubmed: 35361684
pii: gutjnl-2021-325971
doi: 10.1136/gutjnl-2021-325971
doi:

Banques de données

ClinicalTrials.gov
['NCT03458195']

Types de publication

Clinical Trial Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

39-48

Investigateurs

Pierre Cattan Saint-Louis (PC)
Mircea Chirica (M)
Nicolas Munoz-Bongrand (N)
Hélène Corte (H)
Jean-Marc Gornet (JM)
Clotilde Baudry (C)
Nelson Lourenco (N)
Mariane Maillet (M)
My-Linh Tran-Minh (ML)
Andrée Nisard (A)
Laurent Beaugerie Saint-Antoine (LB)
Anne Bourrier (A)
Isabelle Nion-Larmurier (I)
Cecilia Landman (C)
Julien Kirchgesner (J)
Xavier Dray (X)
Ulrika Chaput (U)
Marine Camus (M)
Philippe Marteau (P)
Loic Brot (L)
Najim Chafai (N)
Jeremie H Lefevre (JH)
Clotilde Debove (C)
Yann Parc (Y)
Magali Svreck (M)
Nadia Hoyau-Idrissi (N)
Nathalie Guedj (N)
Yves Panis (Y)
Leon Maggiorri (L)
Mariane Ferron (M)
Yoram Bouhnik (Y)
Olivier Corcos (O)
Gilles Bommelaer (G)
Marion Goutte (M)
Anne Dubois (A)
Caroline Chevarin (C)
Marie Dodel (M)
Dilek Coban (D)
Pierre Desreumaux (P)
Philippe Zerbib (P)
Coralie Sommeville (C)
Virginie Suffys (V)
Jean-Louis Dupas (JL)
Franck Brazier (F)
Clara Yzet (C)
Denis Chatelain (D)
Christophe Attencourt (C)
Charles Sabbagh (C)
Martine Leconte (M)
Bernard Flourié (B)
Yves François (Y)
Eddy Cotte (E)
Anne-Laure Charlois (AL)
Peggy Falgon (P)
Driffa Moussata (D)
Marion Chauvenet (M)
Sarah Boyer (S)
Jérome Filippi (J)
Paul Hofmann (P)
Carole Margalef (C)
Patricia Detre (P)

Commentaires et corrections

Type : CommentIn

Informations de copyright

© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Anthony Buisson (A)

Microbes, Intestin, Inflammation et Susceptibilité de l'Hôte (M2iSH), UMR 1071, USC INRAE 2018, Clermont-Ferrand, France a_buisson@hotmail.fr.
Université Clermont Auvergne, Inserm, 3iHP, CHU Clermont-Ferrand, Service d'Hépato-Gastroentérologie, Clermont-Ferrand, France.

Harry Sokol (H)

Sorbonne Université, INSERM, Centre de Recherche Saint-Antoine, CRSA, AP-HP, Saint Antoine Hospital, Gastroenterology department, F-75012 Paris, France.
Paris Center for Microbiome Medicine (PaCeMM) FHU, Paris, France.
INRAE, UMR1319 Micalis, AgroParisTech, Jouy-en-Josas, France.

Nassim Hammoudi (N)

Gastroenterology Department, Hôpital Saint-Louis hospital, Assitance Publique-Hôpitaux de Paris (AP-HP), Paris, France.
Université De Paris, Institut de Recherche Saint-Louis, EMily, INSERM U1160, F-75010, Paris, France.

Stéphane Nancey (S)

Gastroenterology Department, Centre Hospitalier Lyon-Sud, Pierre-Benite, France.

Xavier Treton (X)

Gastroenterology Department, Hôpital Beaujon, MICI et Assistance Nutritive, APHP, Paris, France.

Maria Nachury (M)

Univ. Lille, Inserm, CHU Lille, U1286 - INFINITE - Institute for Translational Research in Inflammation, F-59000 Lille, France.

Mathurin Fumery (M)

Hepatogastroenterology department, Amiens University Hospital, an Peritox, UMR-I 01, University Amiens, Amiens, France.

Xavier Hébuterne (X)

Gastroenterology and Clinical Nutrition, CHU of Nice and University Côte d'Azur Nice, Nice, France.

Michael Rodrigues (M)

Microbes, Intestin, Inflammation et Susceptibilité de l'Hôte (M2iSH), UMR 1071, USC INRAE 2018, Clermont-Ferrand, France.

Jean-Pierre Hugot (JP)

Centre de recherche sur l'inflammation; INSERM UMR 1149; Assistance Publique-Hôpitaux de Paris; Université de Paris, F-75018 Paris, France.

Gilles Boschetti (G)

Gastroenterology Department, Centre Hospitalier Lyon-Sud, Pierre-Benite, France.

Carmen Stefanescu (C)

Gastroenterology Department, Hôpital Beaujon, MICI et Assistance Nutritive, APHP, Paris, France.

Pauline Wils (P)

Univ. Lille, Inserm, CHU Lille, U1286 - INFINITE - Institute for Translational Research in Inflammation, F-59000 Lille, France.

Philippe Seksik (P)

Sorbonne Université, INSERM, Centre de Recherche Saint-Antoine, CRSA, AP-HP, Saint Antoine Hospital, Gastroenterology department, F-75012 Paris, France.
Paris Center for Microbiome Medicine (PaCeMM) FHU, Paris, France.

Lionel Le Bourhis (L)

Université De Paris, Institut de Recherche Saint-Louis, EMily, INSERM U1160, F-75010, Paris, France.

Madeleine Bezault (M)

Remind study group, Paris, France.

Pierre Sauvanet (P)

Microbes, Intestin, Inflammation et Susceptibilité de l'Hôte (M2iSH), UMR 1071, USC INRAE 2018, Clermont-Ferrand, France.
Chirurgie digestive, CHU Clermont-Ferrand, Clermont-Ferrand, France.

Bruno Pereira (B)

Biostatistics Unit, University Hospital, DRCI, Clermont-Ferrand, France.

Matthieu Allez (M)

Gastroenterology Department, Hôpital Saint-Louis hospital, Assitance Publique-Hôpitaux de Paris (AP-HP), Paris, France.
Université De Paris, Institut de Recherche Saint-Louis, EMily, INSERM U1160, F-75010, Paris, France.

Nicolas Barnich (N)

Microbes, Intestin, Inflammation et Susceptibilité de l'Hôte (M2iSH), UMR 1071, USC INRAE 2018, Clermont-Ferrand, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH